Photo by Welshsk via Wikimedia Commons The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used to manage type 2 diabetes mellitus (T2DM) and obesity, appears to increase the risk of nonscarring hair loss (NSHL). These findings were published online ahead of print in the Journal of the American Academy of Dermatology . In the paper, the authors note that emerging reports suggest potential dermatologic adverse effects associated with GLP-1RA use, particular